Paragonix, a leading provider of advanced organ preservation technologies, has announced that its LUNGguard System has proven effective in reducing post-transplant complications in lung transplant recipients. The study, conducted by a team of researchers, aimed to evaluate the clinical outcomes of lung transplant patients who underwent transplantation with the Paragonix LUNGguard System compared to the conventional ice storage method.
The findings revealed that lung transplant recipients who received lungs preserved using the LUNGguard System experienced a significantly lower incidence of primary graft dysfunction (PGD) grade 3 within the first 72 hours post-transplant. The LUNGguard System, which provides normothermic preservation of donor lungs, ensures the organs are maintained at a physiologically stable temperature, reducing the risk of complications during transplantation.
This breakthrough could have significant implications for the field of lung transplantation, as reducing complications such as PGD can lead to improved patient outcomes and increased transplant success rates. Dr. Anatoliy Pinchuk, CEO of Paragonix, expressed excitement about the study’s results, highlighting the potential of the LUNGguard System to revolutionize lung transplantation and enhance patient care. With further research and development, this innovative organ preservation technology could help address the challenges faced by lung transplant recipients and offer new hope for individuals awaiting life-saving transplants.
